Clinical Trial Update: Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) [Phase 2]

View source ↗

Summary

Phase 2 NeoSPOT trial is evaluating neoadjuvant tislelizumab in combination with chemotherapy for locally advanced oral squamous cell carcinoma and oropharyngea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University Hospital of Stomatology | Conditions: Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING